278 results about "Carcinoma Cell" patented technology

The invention relates to the technical field of biomedicine, in particular to a mouse intrahepatic bile duct cancer cell strain and a construction method and application thereof, the cell strain is named as mouse intrahepatic bile duct cancer cell strain KP-ICC and preserved in China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: C202574; the cell strain is derived from a KrasG12D / Tp53flox / flox C57BL / 6J mouse, a spontaneous tumor model is constructed through high-pressure hydrodynamic tail vein injection of pT3-Cre and a sleep beauty transposase plasmid, and the spontaneous tumor model is obtained through in-vitro culture, passage, monoclonal screening and tumorigenicity verification. The KP-ICC cell strain naturally has chemotherapy-immune combined treatment drug resistance and ferroptosis resistance characteristics, and can be widely applied to the fields of intrahepatic cholangiocarcinoma drug resistance mechanism research, drug resistance reversing, combined treatment drug development, drug resistance animal model establishment and the like.

The invention belongs to the technical field of biological medicine, and provides CKS1B serving as an immunotherapy response prediction biomarker and application of the CKS1B, and according to the application, CKS1B serves as an immunotherapy response marker, and a CKS1B inhibitor is combined with an active component to treat a model mouse. In-vitro cell experiments are adopted to evaluate the immunotherapy prediction effect of the CKS1B as a biomarker on esophageal squamous carcinoma, a Cks1b overexpression tumor mouse model, a homologous mouse model and a human immune reconstruction mouse model are established, and a CKS1B inhibitor is combined with active ingredients to treat the two models; results show that the CKS1B inhibitor combined with the active component can promote removal of esophageal squamous carcinoma cells by CD8 + T cells, inhibit interferon signal channels and antigen presentation, effectively recover immune response, inhibit tumor cell proliferation and significantly reduce tumor volume, so as to achieve the purpose of treating esophageal squamous carcinoma.

The present invention relates to lipid nanoparticle (LNP) compositions, as well as diagnostic or therapeutic polynucleotides, such as TERT mRNA, that can be delivered in a formulation together with the LNP compositions to various tissue and cell types in the whole body of a mammal, such as, for example, TNP mRNA. Comprising stem cells, progenitor cells, germ cells, differentiated cells or terminally differentiated cells, cancer cells, endothelial cells, epithelial cells, splenic cells, hepatocells, kidney cells and / or osteoblasts, for example, for use in the diagnosis, prevention and / or treatment of a condition or disease.

The invention relates to an application of Avasimibe in preparation of a medicine for treating nasopharynx cancer or oral cancer, and belongs to the field of tumor targeted therapy. An in-vitro cell experiment and an in-vivo animal model experiment verify the anti-tumor effect of the compound. Experiments show that Avasimibe can significantly inhibit the activity, proliferation ability, healing ability and cloning ability of nasopharynx cancer cells and oral cancer cells, can regulate cell cycle arrest in a dose-dependent manner, and induces cell apoptosis. In vivo experiments, the tumor volume of nude mice in an Avasimibe treatment group is remarkably reduced, serum cholesterol is remarkably reduced, and serum biochemical analysis shows that compared with a control group, the Avasimibe treatment group has no statistical difference in indexes such as aspartate transaminase (AST) / glutamic-pyruvic transaminase (ALT) and creatinine (Cr). The invention provides a new indication for resisting nasopharynx cancer and oral cancer for the existing compound Avassimibe, has the clinical advantages of low toxicity and capability of overcoming drug resistance, and provides a new treatment choice for patients with nasopharynx cancer and oral cancer.

The invention discloses an application of tripterine in preparation of an anti-esophageal cancer drug. The tripterine or the pharmaceutically acceptable salt thereof provided by the invention can be used for preparing medicines for preventing or treating esophageal cancer. The tripterine is adopted to achieve the effects of inhibiting proliferation of esophageal squamous carcinoma cells, inducing apoptosis of the esophageal squamous carcinoma cells, reducing the size of esophageal tumors and being small in side effect.

The invention belongs to the technical field of biological medicines, and discloses application of decitabine or an optical isomer thereof, or a hydrate thereof, or a solvate thereof, or a prodrug thereof, or a derivative thereof, or a pharmaceutically acceptable salt thereof in preparation of medicines for preventing and / or treating nasopharynx cancer. Or application in preparation of drugs for inhibiting postoperative recurrence and growth of nasopharyngeal carcinoma. In-vivo and in-vitro experiments prove that decitabine has the activity of remarkably inhibiting growth of nasopharyngeal carcinoma cells and is efficient and low in toxicity; the in-situ gel is prepared into the in-situ gel and is locally administrated through the nasopharyngeal cavity, so that toxic and side effects caused by a conventional treatment method can be avoided, tumor recurrence and growth can be remarkably inhibited after nasopharyngeal carcinoma operation, good safety is achieved, a new medicine and a new means are provided for prevention and treatment of nasopharyngeal carcinoma, and therefore the in-situ gel has wide application prospects.

The application discloses a dihydroquinazolinone-containing N-hydroxy amide compound and a preparation method and application thereof, relates to the technical field of medicinal chemistry, and utilizes the splicing principle to design and synthesize dihydroquinazolinone-containing N-hydroxy amide compounds with novel structures, and the compounds are tested in terms of HDAC6 protein affinity and anti-proliferation activity of cervical cancer cell Siha, and the results show that the compounds E1-E5 have better affinity to the HDAC6 protein, the IC 50 values are 4.1-85.4 nM, wherein the affinity of the compound E4 to the HDAC6 protein is higher than that of a positive control SAHA; and the compounds E1-E5 can better inhibit the proliferation of the cervical cancer cell Siha, the IC 50 values are 2.4-9.3 muM, wherein the activity of the compound E4 is the strongest.

The invention discloses an optical positioning method and system for papillary thyroid cancer cells of a terahertz near-field system, and relates to the field of terahertz near-field imaging, and the method comprises the following steps: carrying out the imaging observation of a thyroid tissue section under a first magnification factor through a microscope, carrying out low-magnification imaging partitioning on an area where imaging observation is located according to the morphological characteristics of the cells to form partitioned images; selecting an area of suspected papillary thyroid cancer cells, performing observation and comparison under a second magnification, comparing the observed morphology with the known optical characteristics of the papillary thyroid cancer cells, and selecting an area near the area with the suspected characteristics as an optical positioning point and performing marking; and carrying out positioning according to the optical positioning point, and carrying out scanning imaging by using a terahertz near-field system. The problems that a terahertz near-field system is long in time consumption and difficult to locate when finding papillary cancer cells in multiple cells of thyroid tissue slices are mainly solved.

Proposed are antibodies specifically binding to PTK7 and a use thereof and, more particularly, PTK7 neutralizing antibodies specifically binding to PTK7 to inhibit PTK function, and a use thereof for inhibiting angiogenesis, cell growth, cell migration, and cell invasion. The human PTK7 neutralizing monoclonal antibodies have been found to independently exhibit an effective inhibitory effect on cancer cell growth, migration, invasion in esophageal squamous cell carcinoma and triple-negative breast cancer, and angiogenesis. Therefore, the human PTK7 neutralizing monoclonal antibodies can be applied to various PTK7-positive carcinomas and angiogenic diseases, and can be further developed as a targeted drug therapy for intractable cancers and angiogenic diseases to be used as a core global treatment drug for the same.

A human sebaceous gland carcinoma cell line and use thereof are provided. The human sebaceous gland carcinoma cell line SHNPH-SeC was deposited in the China Center for Type Culture Collection (CCTCC) on Aug. 31, 2023, with an accession number CCTCC NO: C2023113. The human sebaceous gland carcinoma cell line SHNPH-SeC carries a TP53 mutation, and has been identified as a novel single cell line by short tandem repeat (STR) genotyping. This human sebaceous gland carcinoma cell line exhibits strong adherence and stable cellular characteristics, can be stably passaged for multiple generations, and possesses rapid proliferation and migration capabilities, which are in line with the characteristics of malignant tumor cells.

The invention discloses a novel fusobacterium strain Fusobacteria sp.HPSCC05 and an application of the novel fusobacterium strain Fusobacteria sp.HPSCC05. The preservation number of the novel fusobacterium strain Fusobacteria sp.HPSCC05 is CCTCC (China Center For Type Culture Collection) NO: M2025588. According to the invention, Fusobacterium sp.HPSCC05 derived from hypopharyngeal squamous cell carcinoma tissues is successfully separated, the strain has key technical attributes of stable growth, repeatable culture, clear preservation conditions and the like, and the problem of deficiency of current hypopharyngeal carcinoma related strains is solved. Fusobacteria sp.HPSCC05 is identified as a new fusobacterium species, and the blank of hypopharyngeal carcinoma tumor ecological niche specific strain resources is filled up. The method comprises the following steps: establishing an in-vitro verification model (fusobacterium-hypopharyngeal squamous carcinoma cell co-culture model) of the hypopharyngeal carcinoma promoting effect of the Fusobacterium sp.HPSCC05, and providing a replicable culture mode;

The present invention relates to a method of inducing mesenchymal-epithelial transition (MET) in a basal-like (or mesenchymal-like) cancer cell by contacting the cancer cell with an inducer of mesenchymal-epithelial transition for a time and under conditions sufficient to induce MET in the cell. Additionally, there is also provided a method of inhibiting epithelial-mesenchymal transition (EMT) of a cancer in a subject, the method comprising administering an inhibitor or regulator of lipid metabolism for a sufficient time and under conditions to inhibit epithelial mesenchymal transition (EMT) of the cancer in the subject.

The present invention belongs to the field of biomedical technology and discloses an immortalized cell line of human renal chromophobe carcinoma, a culture method and an application thereof. The immortalized cell line of human renal chromophobe carcinoma of the present invention is named human renal chromophobe carcinoma cell line Loya-710 (Homo sapiens), and its Latin name is Chromophobe renal cell carcinoma:Loya‑ 710 , deposited with CCTCC NO: C2025123. The human chromophobe renal cell carcinoma cell line Loya-710, as an in vitro model, grows rapidly in tissue culture and retains the mitochondrial mutations, vesicle structure, and classic immunohistochemical markers characteristic of ChRCC. This invention provides a valuable tool for further studying the genetic, molecular, and biological characteristics of ChRCC and offers a powerful new model for mitochondrial disease.

The invention discloses an application of an LAMP1 inhibitor in preparation of a medicine for preventing and / or treating esophageal cancer. Specifically, the application value of the LAMP1 inhibitor Parishin C in esophageal cancer treatment is found and verified for the first time, invasion and metastasis of esophageal squamous carcinoma cells and in-vivo lymph node metastasis can be remarkably inhibited by targeting LAMP1 protein and downstream signal channels of the LAMP1 protein and Parishin C, and a new drug choice is provided for metastatic esophageal cancer lacking effective treatment means clinically.

The invention relates to the field of biological medicine, in particular to application of NPEPL1-targeted small molecule compounds in preparation of tumor targeted therapy drugs, and four small molecule compounds, namely C301-9181, E859-1332, L281-0443 and C679-2629, which have a hepatocellular carcinoma cell killing effect and high NPEPL1 affinity are obtained for the first time. The small molecule compound realizes tumor targeted therapy by targeting NPEPL1 protein in tumor cells, and can be used for developing tumor targeted therapy drugs. According to the present invention, the potential treatment effect of the targeted intervention NPEPL1 on hepatocellular carcinoma and other malignant solid tumors with high NPEPL1 expression is provided, the optimal small molecule compound C301-9181 is obtained through layer-by-layer screening, the small molecule compound can be used for preparing the NPEPL1-targeting anti-tumor targeting drugs, the drug research and development blank in the NPEPL1 targeting treatment field is filled, and the broad application prospect is provided.

The invention discloses application of a copper carrier in a medicine for enhancing drug resistance of copper death reversing liver cancer cells, and relates to the technical field of medicines. The copper carrier provided by the invention can activate copper death in cisplatin-resistant liver cancer cells in a manner of'three-arrow simultaneous shooting '. The method mainly comprises the following steps: increasing the number of copper ions entering cells (a first'arrow '), consuming GSH to reduce the loss of copper ions in the cells (a second'arrow'), and down-regulating the expression of ATP7B to inhibit the outflow of copper ions (a third'arrow '). Besides, the copper carrier down-regulates copper death related proteins (FDX1, DLAT, ATP7B and LIAS), also down-regulates drug resistance related proteins (ATP7B and P-gp), and shows a remarkable anti-liver cancer curative effect. Particularly, the bCCM can target mitochondria, improve the mitochondrial copper ion level, consume mitochondrial GSH and cause mitochondrial dysfunction mediated by copper death, and the bCCM and the cis-platinum have a remarkable synergistic effect and can reverse the drug resistance of the cis-platinum.

The application belongs to the technical field of biological medicine, and particularly relates to application of long-chain non-coding RNA expression inhibition in esophageal cancer ferroptosis inducer sensitization. The application first reveals dynamic change of long-chain non-coding RNA ENSG00000250658 in esophageal squamous cell carcinoma metastasis based on single-cell sequencing data, detects expression of ENSG00000250658 in esophageal squamous cell carcinoma tissue and correlation with prognosis by using LNA probe-based RNA in-situ hybridization technology, and first finds that knocking down ENSG00000250658 can increase killing effect of ferroptosis inducer on esophageal squamous cell carcinoma cells. Therefore, the application provides a new technical scheme and thought for clinical diagnosis and treatment of esophageal cancer.

The invention belongs to the technical field of biological medicine, and particularly relates to a biomarker related to acetylation of a K147 site of histone H1 and application of the biomarker in liver cancer treatment. The invention relates to a biomarker related to acetylation of a K147 site of histone H1. According to the biomarker, the histone H1 is subjected to acetylation modification at the K147 site. Bioinformatics analysis shows that the high expression state of acetyltransferase ELP3 is closely related to the occurrence and development of hepatocellular carcinoma, ELP3 can directly regulate and control acetylation modification of histone H1, then the core catalytic site of ELP3 is verified through site mutation, and the K147 acetylation site located on the histone H1 is precisely determined. Test results show that intervention of the ELP3-H1-K147 pathway can significantly inhibit proliferation and migration ability of liver cancer cells, and can provide research and development direction and theoretical support for development of novel liver cancer treatment drugs.

This invention relates to drug-resistant breast cancer cells and their applications, belonging to the field of tumor cell technology. The drug-resistant breast cancer cells of this invention are human mammary ductal carcinoma cells T47DR and / or human breast cancer cells MCF7R. The human mammary ductal carcinoma cells T47DR were deposited at the Guangdong Provincial Microbial Culture Collection Center on October 25, 2024, with accession number GDMCC No: 65348; the human breast cancer cells MCF7R were deposited at the same center on October 25, 2024, with accession number GDMCC No: 65347. This invention demonstrates that the clonogenic ability, migration ability, anti-apoptotic ability, and spheroidization ability of drug-resistant breast cancer cells are significantly enhanced. They can form tumors independently of estrogen and metastasize throughout the body in a short period of time. The tumor stemness of the drug-resistant cells is enhanced, and they exhibit resistance to apelexifen and / or tamoxifen.

The application belongs to the field of medicine, and particularly relates to application of CZC-54252 in preparation of a drug for treating esophageal squamous cell carcinoma. The results of the application show that CZC-54252 can efficiently inhibit expression of RSK4 enzyme, and can efficiently inhibit proliferation, invasion and migration of esophageal squamous cell carcinoma cells. In combination with Afatinib, the proliferation of an esophageal squamous cell carcinoma erlotinib-resistant strain can be significantly inhibited, and the results provide an effective technical means for treatment and prognosis of esophageal squamous cell carcinoma patients.

The invention discloses application of DNASE1L3, CYP4B1 and / or FAM65B in enhancing the cisplatin sensitivity of nasopharyngeal carcinoma, and belongs to the field of biological medicine. The invention proves that overexpression of the DNASE1L3 gene, the CYP4B1 gene and / or the FAM65B gene can obviously inhibit the activity of nasopharyngeal carcinoma cells and obviously enhance the sensitivity of the nasopharyngeal carcinoma cells to cis-platinum. An in-vivo xenotransplantation tumor model further proves that the in-vivo anti-tumor effect of the cis-platinum can be remarkably enhanced by combining the overexpressed DNASE1L3 gene, the CYP4B1 gene or the FAM65B gene with the cis-platinum, and tumor growth is effectively inhibited. The invention provides a brand new molecular target for overcoming the cisplatin resistance of nasopharynx cancer, provides a new strategy for preparing high-efficiency and low-toxicity nasopharynx cancer treatment drugs and cisplatin sensitizers, and has important clinical application prospects and market values.

The application discloses application of CPSF7 as an ovarian cancer treatment and prognosis target, and relates to the technical field of biological medicine.The application research finds that overexpression of CPSF7 is related to poor prognosis of ovarian cancer, indicating that CPSF7 can be used as a prognosis index and potential treatment target of ovarian cancer.Further research shows that CPSF7 promotes malignant progression of ovarian cancer by promoting proliferation, migration and invasion of ovarian cancer cells, and inhibition of CPSF7 expression can significantly inhibit proliferation, migration and invasion of ovarian cancer cells.The application also finds that UBE2K is one of key downstream targets of CPSF7 in the ovarian cancer cell-mediated carcinogenic process, and inhibition of UBE2K expression can weaken the overexpression of CPSF7 induced enhancement effect of ovarian cancer cell proliferation, migration and invasion.The application provides a new target for treatment and prognosis prediction of ovarian cancer, and has important clinical application value.

The present application relates to compounds of formula (A) that inhibit the growth of cancers that express G12D mutant Ras proteins. The molecules of the specification are thus indicated for use in the treatment of cancer that express G12D mutant Ras protein.

The invention provides a traditional Chinese medicine preparation for treating liver cancer, and relates to the technical field of traditional Chinese medicine preparation. The traditional Chinese medicine preparation is prepared from radix fici simplicissimae, euphorbia helioscopia, herba ardisiae japonicae, pollen typhae, ginseng, radix gentianae macrophyllae, cortex eucommiae, citrus aurantium, sambucus chinensis, hypericum japonicum and fructus ziziphi jujubae. In the formula, radix fici simplicissimae and euphorbia helioscopia are used as monarch drugs, herba ardisiae japonicae, pollen typhae, ginseng and gentiana macrophylla are used as ministerial drugs, citrus aurantium, sambucus chinensis, hypericum japonicum and eucommia ulmoides are used as adjuvant drugs, Chinese dates are used as conductant drugs, and the medicines in the whole formula are reasonably matched in monarch, ministerial, adjuvant and conductant drugs, give consideration to body resistance strengthening and evil eliminating, and jointly achieve the effects of tonifying qi, strengthening body resistance, dispersing blood stasis, detoxifying, clearing heat, promoting diuresis, soothing liver and regulating qi. The traditional Chinese medicine preparation has a remarkable inhibiting effect on proliferation, migration and invasion of hepatoma carcinoma cells, can effectively reduce the tumor volume and weight of tumor-bearing mice, slows down the tumor growth speed, can effectively improve the immune organ index and immune cell factors of the tumor-bearing mice, has an immunological enhancement effect, and can be used for treating liver cancer. The traditional Chinese medicine preparation is expected to serve as a new choice of medicines for treating liver cancer.

The application provides an oxazinane compound, a preparation method, a pharmaceutical composition and application, and a general formula of the oxazinane compound or a pharmaceutically acceptable salt thereof is shown as formula (I). The oxazinane compound has obvious proliferation inhibition effect on cancer cells, especially human head and neck squamous cell carcinoma cell strains HSC4, HSC3, HSC2, CAL33, SCC4 and human glioma cell strain U251, can block the cell cycle, effectively inhibit the phosphorylation level of key proteins in the PI3K / AKT / mTOR pathway at the molecular level, has the potential to be prepared into a new antitumor drug, and has a good market prospect.

The present invention relates to an antitumor adenovirus capable of evading the in vivo immune system. According to the present invention, the adenovirus comprising a nucleic acid coding for a transferrin-binding domain of the present invention exhibits notably increased effects of infecting and killing tumor cells, exhibits increased binding to transferrin, thereby evading an in vivo immune response and thus increasing the plasma half-life, has a systemic therapeutic effect by being specifically delivered to cancer cells, is capable of being topically delivered, and has excellent selectivity, thereby exhibiting the effect of notable antitumor efficacy, and thus may be usefully employed as an anticancer composition or an anticancer adjuvant for various carcinomas.

Substances and methods are disclosed for reducing or preventing metastatic behaviour in VGSC expressing cancer by the effect of at least reducing the persistent part of the voltage gated sodium channel current without eliminating the transient part. Inhibition of metastatic cell behaviours such as detachability, lateral motility, transverse migration and invasiveness is demonstrated using the known drugs ranolazine and riluzole.

The invention relates to the technical field of biomedical imaging and terahertz detection, in particular to a terahertz near-field imaging quality analysis system and method. According to the technical scheme, the system comprises an atomic force microscope system, a terahertz source, an image acquisition module, an image scoring module and a data processing module, and the atomic force microscope system adopts a tapping mode based on the terahertz scattering type scanning near-field optical microscope technology and comprises a Z voltage control unit used for adjusting the probe insertion depth; the terahertz source is used for providing terahertz waves required by imaging, and the terahertz source and the probe module of the atomic force microscope system are coaxially arranged. By quantifying the association rule of the probe insertion depth and the imaging quality, the core pain points of blind parameter adjustment and unstable quality in terahertz near-field imaging are solved at one stroke, the imaging consistency is greatly improved, the detection process and the quality evaluation system are exclusive, the method is particularly suitable for undyed paraffin sections, and the detection accuracy is improved. And the pathological characteristics of papillary carcinoma cells can be clearly presented.

The present invention relates generally to a method of detecting inhibitory effects of health supplements on serine protease in cell lines derived from human carcinomas. More, particularly, the present invention relates to inhibitory analysis of health supplementary products taken from market and / or chemically purified forms, in order to determine their competitors and / or inhibitory effects on serine protease such as trypsin so that these supplements can be used for the treatment once someone develop intense inflammatory reactions either due to infections like COVID-19 and / or pathological conditions such as cancer. The present invention further provides therapeutic applications for agents and / or condition which utilize human enzymatic system and / or cellular components for the development of pathological conditions.

The invention discloses a cyclic iridium-ester tin imidazo phenanthroline complex with an aggregation-induced emission (AIE) characteristic as well as a preparation method and an anti-cancer application of the cyclic iridium-ester tin imidazo phenanthroline complex. The structural formula is as shown in formula (I), R1 is phenyl or 3-pyridyl, and R2 is hydrogen or fluorine. By testing the growth inhibition rate of the target compound on human alveolar basal epithelial cancer cells (A549) and comparing, the target compound shows potential A549 cell proliferation inhibition activity. In addition, the target complex shows a unique AIE luminescence characteristic, and is accumulated in lysosome of A549 cells, resulting in lysosome damage and apoptosis.